Format

Send to

Choose Destination
Future Oncol. 2016 Mar;12(5):637-45. doi: 10.2217/fon.16.2. Epub 2016 Feb 3.

Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma.

Author information

1
Division of Radiation Oncology & Cancer Imaging, Peter MacCallum Cancer Center, East Melbourne, Australia.
2
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH, USA.
3
Houston Methodist Hospital, Weil Cornell Medical College, Houston, TX, USA.
4
Beth Israel Deaconess Medical Center, Boston, MA, USA.
5
University of Munich Hospitals, Munich, Germany.
6
Department of Radiology, University of Yamanashi, Yamanashi, Japan.
7
Karolinska University Hospital/Karolinska Institute, Stockholm, Sweden.
8
National Institute of Radiological Sciences, Chiba, Japan.

Abstract

AIM:

To provide a multi-institutional consensus document for stereotactic body radiotherapy of primary renal cell carcinoma.

MATERIALS & METHODS:

Eight international institutions completed a 65-item survey covering patient selection, planning/treatment aspects and response evaluation.

RESULTS:

All centers treat patients with pre-existing hypertension and solitary kidneys. Five institutions apply size constraints of 5-8 cm. The total planning target volume expansion is 3-10 mm. All institutions perform pretreatment imaging verification, while seven institutions perform some form of intrafractional monitoring. Number of fractions used are 1-12 to a total dose of 25 Gy-80 GyE. Imaging follow-up for local tumor response includes computed tomography (n = 8), PET-computed tomography (n = 1) and MRI (n = 5). Follow-up frequency is 3-6 months for the first 2 years and 3-12 months for subsequent 3 years.

CONCLUSION:

Key methods for safe implementation and practice for stereotactic body radiotherapy kidney have been identified and may aid standardization of treatment delivery.

KEYWORDS:

SABR; SBRT; ablation; kidney cancer; patterns of practice; radiotherapy; stereotactic

PMID:
26837701
DOI:
10.2217/fon.16.2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center